RECRUITINGINTERVENTIONAL
Autologous Serum Eye Drops in Dry Eye Syndrome
Autologous Serum Eye Drops in Dry Eye Syndrome: Clinical Efficacy and Safety Evaluation
About This Trial
This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.
Who May Be Eligible (Plain English)
Who May Qualify:
- Children aged less than 18 years.
- Both sexes.
- Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears.
Who Should NOT Join This Trial:
- Active ocular infection.
- Recent ocular surgery.
- Systemic immunosuppressive therapy.
- History of allergy to blood-derived products.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Children aged less than 18 years.
* Both sexes.
* Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears.
Exclusion Criteria:
* Active ocular infection.
* Recent ocular surgery.
* Systemic immunosuppressive therapy.
* History of allergy to blood-derived products.
Treatments Being Tested
OTHER
Autologous Serum Eye Drop
Participants will receive eye drops prepared from their blood serum following a standardized protocol. Specifically, 40 mL of venous blood was collected from each participant at the start of the study and centrifuged at 3000 rpm for 15 min.
Locations (1)
The General Authority for Teaching Hospitals and Institutes
Cairo, Egypt